Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.66 |
| ▸ | CDK4 | P11802 | 1/20 | 0.55 |
| ▸ | CCND1 | P24385 | 1/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | BCR | P11274 | 1/20 | 0.49 |
| ▸ | XDH | P47989 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2553748 | 1.00 | ERN1 (0.66) | ERN1CDK4CCND1ABL1ABCB1 | |
| SCHEMBL31074940 | 0.85 | CDK4 (0.55) | ERN1CDK4CCND1XDHHSP90AA1 | |
| SCHEMBL20292376 | 0.85 | CDK4 (0.55) | ERN1CDK4CCND1XDHHSP90AA1 | |
| SCHEMBL11530954 | 0.82 | ERN1 (0.96) | ERN1MEN1KMT2ALMNAMAPT | |
| SCHEMBL3437049 | 0.80 | ALDH1A1 (0.59) | CDK4CCND1XDHMEN1KMT2A | |
| SCHEMBL28908860 | 0.80 | TDP1 (0.47) | ERN1CDK4CCND1XDHMAPK1 | |
| SCHEMBL28908861 | 0.80 | TDP1 (0.47) | ERN1CDK4CCND1XDHMAPK1 | |
| SCHEMBL3437050 | 0.80 | ALDH1A1 (0.59) | CDK4CCND1XDHMEN1KMT2A | |
| SCHEMBL247839 | 0.79 | ERN1 (1.00) | ERN1MEN1KMT2ALMNAMAPT | |
| SCHEMBL29694515 | 0.79 | ERN1 (1.00) | ERN1MEN1KMT2ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| US-10179781-B2 | Sodium channel modulators for the treatment of pain | CHROMOCELL CORPORATION | 2019-01-15 | — | — | US | disclosed |
| US-10179781-B2 | Sodium channel modulators for the treatment of pain | CHROMOCELL CORPORATION | 2019-01-15 | — | — | US | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| EP-3043787-B1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN AND DIABETES | CHROMOCELL CORP (US) | 2018-09-05 | — | — | EP | disclosed |
| EP-2968234-B1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | CHROMOCELL CORP (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-2968234-B1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | CHROMOCELL CORP (US) | 2018-06-27 | — | — | EP | disclosed |
| US-20170304306-A1 | SELECTIVE NaV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES | CHROMOCELL CORPORATION (US) | 2017-10-26 | — | — | US | disclosed |
| US-20160046617-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | CHROMOCELL CORPORATION (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160046617-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | CHROMOCELL CORPORATION (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160046617-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | CHROMOCELL CORPORATION (US) | 2016-02-18 | — | — | US | disclosed |
| EP-2968234-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | Chromocell Corporation (US) | 2016-01-20 | — | — | EP | disclosed |
| CN-105188694-A | Sodium channel modulators for the treatment of pain | CHROMOCELL CORP | 2015-12-23 | — | — | CN | disclosed |
| WO-2014151472-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | CHROMOCELL CORPORATION (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014151472-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | CHROMOCELL CORPORATION (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179781-B2 | Sodium channel modulators for the treatment of pain | SCN7A, SCN10A, SCN2A | ERN1 3345/4885CDK4 4331/4885CCND1 4641/4885 |
| US-20160046617-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | SCN7A, SCN10A, SCN2A | ERN1 3345/4885CDK4 4331/4885CCND1 4641/4885 |
| US-20170304306-A1 | SELECTIVE NaV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES | SCN7A, SCN1A, SCN1B | ERN1 1538/4885CDK4 2322/4885CCND1 2455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.